Current use of the Tumor Mutational Burden Biomarker to Guide Treatment Decisions in Adults with Advanced Metastatic Non-Small Cell Lung Cancer – A Retrospective Observational Study
Abstract Background: Immunotherapy has become first-line in metastatic non-small cell lung cancer (NSCLC). Biomarkers are used to help identify individual patients for potential response to…
